Skip to main content
. Author manuscript; available in PMC: 2021 May 3.
Published in final edited form as: Am J Obstet Gynecol MFM. 2020 Oct 27;3(1):100275. doi: 10.1016/j.ajogmf.2020.100275

FIGURE 2. HUVECs exhibit impaired respiration with elevated mitochondrial ROS.

FIGURE 2

A, Cell respiration is reduced in HUVECs treated with PE patient serum (PE at <34 weeks’ gestation [n=6]; PE at >34 weeks’ gestation [n=4]). HUVECs treated with 10% preeclamptic serum from PE patients at <34 weeks’ gestation show a significant reduction in the uncoupled respiration rate vs the cells that were treated with nonpreeclamptic serum (n=8). B, The mitochondrial ROS in HUVECs treated with preeclamptic serum (PE at <34 weeks’ gestation [n=6]; PE at >34 weeks’ gestation [n=4]) or with nonpreeclamptic serum (n=8). HUVECs treated with 10% serum from preeclamptic patients at <34 weeks’ gestation showed a significant increase in the mitochondrial ROS production when compared with nonpreeclamptic serum. Data are presented as the mean±standard deviation. The asterisk indicates a significant (P<.05) difference from the control group.

CRTL, control; ET, electron transport; PE, preeclampsia; ROS, reactive oxygen species.